BenevolentAI SA
AEX:BAI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
BenevolentAI SA
AEX:BAI
|
11.6m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
280.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
275.5B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.5B EUR |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for BenevolentAI SA is -919.3%, which is below its 3-year median of -823.1%.
Over the last 7 months, BenevolentAI SA’s Net Margin has decreased from -749.4% to -919.3%. During this period, it reached a low of -896.7% on Jul 30, 2024 and a high of -749.4% on Dec 1, 2023.
